Learn › Weight Loss

GLP-1 Receptor Agonists Explained: How They Work and Which to Choose

By Truventa Medical Clinical Team · Updated April 2025 · 8 min read

GLP-1 receptor agonists have fundamentally changed how medicine approaches weight loss. These medications — which include household names like Ozempic, Wegovy, Mounjaro, and Zepbound — don't work like any diet pill before them: they reprogram your appetite, slow digestion, and optimize blood sugar in ways that produce weight loss of 15–21% of body weight on average. Here's a complete guide to how GLP-1 receptor agonists work and how to choose the right one for your situation.

What Are GLP-1 Receptor Agonists?

GLP-1 receptor agonists (GLP-1 RAs) are a class of medications that mimic glucagon-like peptide-1 — a hormone your gut naturally produces in response to eating. GLP-1 is an incretin hormone: it signals to multiple organ systems that food has been consumed, triggering a coordinated metabolic response that includes insulin secretion, appetite suppression, and slowed gastric emptying.

The natural form of GLP-1 is rapidly broken down in the body — its half-life is less than 2 minutes. GLP-1 receptor agonists are synthetic molecules designed to bind the same receptor but resist degradation, producing effects that last hours to a week depending on the formulation.

These medications were originally developed for type 2 diabetes — their ability to lower blood sugar was discovered first. The profound weight loss they produced was initially observed as a "side effect" of diabetic patients in early trials. This observation led directly to the dedicated obesity formulations that now include Wegovy and Zepbound.

Mechanism of Action: How GLP-1 Receptor Agonists Work

1. Appetite Suppression (Central Nervous System)

The most clinically important mechanism of GLP-1 RAs for weight loss is their action in the brain. GLP-1 receptors are densely expressed in the hypothalamus (particularly the arcuate nucleus), the brainstem, and the mesolimbic reward pathway.

When GLP-1 receptors are activated in these brain regions:

• Satiety signals increase: You feel full sooner and more completely after eating
• Hunger signals decrease: The hypothalamic hunger circuits (particularly neuropeptide Y / AgRP neurons) are suppressed
• Food reward is reduced: The hedonic drive to eat — especially highly palatable, calorie-dense foods — is significantly blunted. Many patients describe losing interest in foods they previously craved compulsively
• "Food noise" quiets: The constant mental preoccupation with food that many overweight individuals experience largely disappears for most GLP-1 RA users

This central appetite suppression is the primary driver of weight loss. Patients simply eat substantially less — not through willpower, but because the neurological drive to eat is biochemically reduced.

2. Slowed Gastric Emptying

GLP-1 receptors in the gut and vagus nerve slow the rate at which food moves from the stomach into the small intestine. This gastroparesis-like effect produces several important consequences:

• Food stays in the stomach longer, maintaining satiety signals after meals
• Post-meal blood sugar spikes are blunted because glucose absorption is slower and more gradual
• Meal volume tolerance decreases — many patients can comfortably eat only small portions before feeling uncomfortably full

This mechanism also accounts for the most common side effects: nausea, bloating, and constipation — all direct consequences of slowed gastric transit. These effects typically diminish as the body adapts over the first 4–12 weeks.

3. Insulin Secretion and Glucose Regulation

In the pancreas, GLP-1 receptor activation stimulates glucose-dependent insulin secretion from beta cells. Critically, this insulin release is glucose-dependent — GLP-1 RAs only increase insulin when blood glucose is elevated. This means they have an extremely low risk of causing hypoglycemia (unlike sulfonylureas or insulin).

Simultaneously, GLP-1 RAs suppress glucagon secretion from alpha cells, further reducing hepatic glucose output. The net effect is excellent glucose control with a favorable safety profile.

For weight loss purposes, the improved insulin sensitivity and glucose handling these drugs provide also helps optimize fat metabolism — insulin is a powerful driver of fat storage, so reducing insulin spikes reduces lipogenesis.

4. Cardiovascular and Metabolic Effects

GLP-1 receptors are expressed in the heart, blood vessels, kidneys, and liver. Beyond weight loss and glucose control, GLP-1 RAs have demonstrated:

• Reduced major cardiovascular events: Multiple large trials (LEADER, SUSTAIN-6, SELECT) show 20–26% reductions in MACE (heart attack, stroke, cardiovascular death) in high-risk patients
• Blood pressure reduction: Typically 3–5 mmHg systolic reduction
• Anti-inflammatory effects: Reduced systemic inflammation markers including CRP
• Kidney protection: Reduced proteinuria and slowed progression of diabetic kidney disease

FDA-Approved GLP-1 Receptor Agonists: The Complete List

For Weight Management (Obesity Indications)

• Wegovy (semaglutide 2.4 mg weekly injection) — Novo Nordisk, FDA-approved June 2021. Produces ~15% average weight loss in the STEP trials. Gold standard for GLP-1 monotherapy weight loss.
• Zepbound (tirzepatide weekly injection) — Eli Lilly, FDA-approved November 2023. Dual GLP-1/GIP agonist producing ~20% average weight loss. Currently the most effective weight loss drug available.
• Saxenda (liraglutide 3.0 mg daily injection) — Novo Nordisk, FDA-approved 2014. Older GLP-1 RA producing ~5–8% weight loss. Now largely superseded by weekly formulations but still prescribed in some cases.
• Qsymia / Contrave — Not GLP-1 RAs; included for reference. Older non-GLP-1 obesity drugs.

For Type 2 Diabetes (with Weight Loss as Secondary Benefit)

• Ozempic (semaglutide 0.5–2.0 mg weekly injection) — Same molecule as Wegovy but at a lower maximum dose, FDA-approved for type 2 diabetes. Often prescribed off-label for weight loss.
• Mounjaro (tirzepatide weekly injection) — Same molecule as Zepbound, FDA-approved for type 2 diabetes. Often prescribed off-label for weight loss.
• Rybelsus (oral semaglutide 3–14 mg daily) — First FDA-approved oral GLP-1 RA, approved for type 2 diabetes. Produces meaningful weight loss (~3–4 kg) but less than injectable versions. Requires strict morning dosing protocol (taken with minimal water, 30+ minutes before eating).
• Trulicity (dulaglutide weekly injection) — Modest weight loss (~2–3 kg). Primarily a diabetes drug.
• Victoza (liraglutide 1.2–1.8 mg daily injection) — Predecessor to Saxenda at lower doses.
• Byetta / Bydureon (exenatide) — First GLP-1 RA approved (2005). Weekly extended-release version (Bydureon) still used. Modest weight loss; largely supplanted by newer agents.

Dual Agonists: GLP-1 + GIP (The Next Generation)

The most significant advance in GLP-1 therapy has been the development of dual agonists — medications that activate both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously.

Tirzepatide (Zepbound/Mounjaro) is the first approved dual GLP-1/GIP agonist. GIP receptors, when activated simultaneously with GLP-1 receptors, appear to produce synergistic effects on appetite suppression and fat metabolism. The SURMOUNT trials showed tirzepatide produced 20–22% average body weight reduction at the highest dose — meaningfully greater than semaglutide's ~15%.

Next in the pipeline: retatrutide (triple agonist: GLP-1 + GIP + glucagon receptor), currently in Phase 3 trials with preliminary data showing up to 24% weight loss. This class of drugs continues to evolve rapidly, with each generation producing incrementally greater efficacy.

Compounded GLP-1 Receptor Agonists

Given brand-name costs of $1,000–$1,350 per month, compounded versions of GLP-1 RAs have become a major part of the market. FDA-registered 503B compounding pharmacies can produce compounded semaglutide and compounded tirzepatide at a fraction of brand-name cost.

At Truventa Medical, we offer both compounded semaglutide and compounded tirzepatide through our telehealth platform. These contain the same active pharmaceutical ingredients as Ozempic/Wegovy and Mounjaro/Zepbound respectively, prepared under pharmaceutical-grade conditions. See our tirzepatide and semaglutide pages for clinical details, and our pricing page for current costs.

How to Choose the Right GLP-1 Receptor Agonist

With multiple options available, here's a practical framework for choosing:

Choose Semaglutide (Wegovy/Ozempic) If:

• Your insurance covers Wegovy/Ozempic but not tirzepatide
• You have type 2 diabetes and need an established GLP-1 with robust cardiovascular data
• You've had GI side effects with tirzepatide in the past
• Cost considerations favor semaglutide compounded options
• You prefer once-weekly dosing with a very well-characterized safety profile (semaglutide has 10+ years of diabetes data)

Choose Tirzepatide (Zepbound/Mounjaro) If:

• Maximizing weight loss is the primary goal (20–22% vs. ~15% average)
• Your insurance covers Zepbound, or you're accessing via Lilly Direct self-pay program
• You have type 2 diabetes with suboptimal control on a GLP-1 alone
• You've tried semaglutide and want to try a more potent option

Choose Oral Semaglutide (Rybelsus) If:

• You have needle aversion and cannot use injectables
• You have type 2 diabetes with modest weight loss goals
• You can commit to the strict morning dosing protocol

Talk to a Provider First

Individual response to GLP-1 RAs varies significantly. Some patients who don't lose weight on semaglutide respond well to tirzepatide and vice versa. Your medical history, insurance coverage, GI tolerability, and weight loss goals should all factor into the choice. A licensed provider can review your complete health picture and recommend the right starting point.

How to Access GLP-1 Therapy via Telehealth

Truventa Medical offers GLP-1 receptor agonist therapy through our telehealth platform — no in-person visits required, available in all 50 states. Our providers:

• Evaluate your medical history and weight loss history
• Review labs (or order them if needed)
• Write prescriptions for compounded or brand-name GLP-1 medications
• Provide titration guidance and ongoing support
• Monitor for side effects and adjust your protocol as needed

To get started, complete a free consultation. You'll connect with a licensed physician or NP who specializes in weight management and can have your prescription on its way within days.